Sci Pharmtech Stock EBITDA
| 4119 Stock | TWD 90.60 1.90 2.05% |
SCI Pharmtech fundamentals help investors to digest information that contributes to SCI Pharmtech's financial success or failures. It also enables traders to predict the movement of SCI Stock. The fundamental analysis module provides a way to measure SCI Pharmtech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to SCI Pharmtech stock.
SCI |
SCI Pharmtech Company EBITDA Analysis
SCI Pharmtech's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current SCI Pharmtech EBITDA | 129.25 M |
Most of SCI Pharmtech's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, SCI Pharmtech is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
According to the company disclosure, SCI Pharmtech reported earnings before interest,tax, depreciation and amortization of 129.25 M. This is 85.27% lower than that of the Pharmaceuticals sector and 78.05% lower than that of the Health Care industry. The ebitda for all Taiwan stocks is 96.68% higher than that of the company.
SCI EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses SCI Pharmtech's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of SCI Pharmtech could also be used in its relative valuation, which is a method of valuing SCI Pharmtech by comparing valuation metrics of similar companies.SCI Pharmtech is currently under evaluation in ebitda category among its peers.
SCI Fundamentals
| Return On Equity | 0.0609 | |||
| Return On Asset | 0.0077 | |||
| Profit Margin | 0.26 % | |||
| Operating Margin | 0.07 % | |||
| Current Valuation | 9.19 B | |||
| Shares Outstanding | 95.38 M | |||
| Shares Owned By Insiders | 48.80 % | |||
| Shares Owned By Institutions | 0.77 % | |||
| Price To Earning | 14.98 X | |||
| Price To Book | 2.62 X | |||
| Price To Sales | 11.33 X | |||
| Revenue | 864.22 M | |||
| Gross Profit | 208.09 M | |||
| EBITDA | 129.25 M | |||
| Net Income | 55.7 M | |||
| Cash And Equivalents | 1.01 B | |||
| Cash Per Share | 12.73 X | |||
| Total Debt | 3.65 M | |||
| Debt To Equity | 0.10 % | |||
| Current Ratio | 3.24 X | |||
| Book Value Per Share | 37.30 X | |||
| Cash Flow From Operations | 280.28 M | |||
| Earnings Per Share | 2.13 X | |||
| Target Price | 86.0 | |||
| Number Of Employees | 14 | |||
| Beta | -0.0933 | |||
| Market Capitalization | 9.59 B | |||
| Total Asset | 4.19 B | |||
| Retained Earnings | 809 M | |||
| Working Capital | 1.02 B | |||
| Current Asset | 1.8 B | |||
| Current Liabilities | 782 M | |||
| Annual Yield | 0.01 % | |||
| Five Year Return | 4.21 % | |||
| Net Asset | 4.19 B |
About SCI Pharmtech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze SCI Pharmtech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of SCI Pharmtech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of SCI Pharmtech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for SCI Stock Analysis
When running SCI Pharmtech's price analysis, check to measure SCI Pharmtech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SCI Pharmtech is operating at the current time. Most of SCI Pharmtech's value examination focuses on studying past and present price action to predict the probability of SCI Pharmtech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SCI Pharmtech's price. Additionally, you may evaluate how the addition of SCI Pharmtech to your portfolios can decrease your overall portfolio volatility.